The clinical profile of the angiotensin II receptor blocker eprosartan

Journal of Hypertension

Volumn 20, Issue SUPPL. 5, 2002, Pages

  Hedner, Thomas ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin; Angiotensin II; Angiotensin converting enzyme inhibitors; Antihypertensive agents; Eprosartan; Hypertension; Receptors; Sympathetic nervous system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; CYTOCHROME P450; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMBUSARTAN; ENALAPRIL; EPROSARTAN; FLUCONAZOLE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; LOSARTAN; RANITIDINE; VALSARTAN; WARFARIN; ACRYLIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR; IMIDAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

CONFERENCE PAPER; COUGHING; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; HEADACHE; HUMAN; LONG TERM CARE; NORADRENALIN RELEASE; PRIORITY JOURNAL; ANIMAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG INTERACTION; HYPERTENSION; METABOLISM; REVIEW;

ACRYLATES; ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; IMIDAZOLES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; THIOPHENES;

EID: 0036600283     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200212000-00001     Document Type: Conference Paper

References (25)

1. Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive patient
2. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
3. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy
4. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management
5. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors
6. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors
7. Clinical efficacy of eprosartan
8. Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data
9. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566
10. A review of eprosartan pharmacokinetics and pharmacodynamic interaction studies
11. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade
12. Control of cardiomyocyte gene expression as drug target
13. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: Comparison between valsartan, candesartan, eprosartan and embusartan
14. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure
15. Stress, autonomic hyperactivity and essential hypertension: An enigma
16. The metabolic fate of eprosartan in healthy subjects
17. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
18. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients
19. Eprosartan versus enalapril in elderly patients with hypertension: A double-blind, randomized trial
20. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension
21. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: Subgroup analysis of a 26-week, double-blind, multicentre study
22. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: Results from a 26-week, double-blind, multicentre study
23. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension
24. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension